Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    ARCHAIC -hydroxychloroquine, 2020
     
    NL8490
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
    9/6 inconclusive
      CCAP-1, 2020
       
      NCT04345289
      RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
      -/- inconclusive
        Chen, 2020
         
        NCT04384380
        RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        21/12 inconclusive
          Duke university HCQ, 2020
           
          NCT04335552
          RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
          4/2 no results
            discontinued, found in Axfors et al. meta-analysis
            HAHPS, 2020
             
            NCT04329832
            RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
            42/43 inconclusive
            • inconclusive 7 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
            Huang, 2020
             
            ChiCTR2000029542
            RCTchloroquinelopinavir/ritonavirCOVID 19 hospitalizedsome concern
            10/12 inconclusive
              HYCOVID, 2020
               
              NCT04325893
              RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
              124/123 inconclusive
              • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
              NO COVID-19 (Lyngbakken), 2020
               
              NCT04316377
              RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
              27/26 inconclusive
                OAHU-COVID19, 2020
                 
                NCT04345692
                RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
                10/6 inconclusive
                  ORCHID, 2020
                   
                  NCT04332991
                  RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
                  242/237 inconclusive
                  • inconclusive 2 % increase in clinical improvement (PE) with a high degree of certainty due to low risk of bias
                  PROTECT B, 2020
                   
                  NCT04338698
                  RCThydroxychloroquineoseltamivirCOVID 19 hospitalizedNA
                  -/- inconclusive
                    RECOVERY, 2020
                     
                    NCT04381936
                    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                    1561/3155 safety concern
                    • inconclusive 9 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                    • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
                    Sekhavati, 2020 RCThydroxychloroquinelopinavir/ritonavirCOVID 19 hospitalizedsome concern
                    56/55 inconclusive
                    • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                    Sekhavati, 2020 RCThydroxychloroquinehydroxychloroquineCOVID 19 hospitalizedsome concern
                    56/55 inconclusive
                    • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
                    SOLIDARITY (WHO study) HCQ, 2020
                     
                    NCT04315948
                    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                    947/906 inconclusive
                    • inconclusive 19 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                    Tang, 2020
                     
                    ChiCTR2000029868
                    RCTchloroquine and derivativesstandard of careCOVID 19 hospitalizedhigh
                    75/75 inconclusive
                      Tang, 2020
                       
                      ChiCTR2000029868
                      RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
                      75/75 safety concern
                      • statistically significant 3.5-fold increase in adverse events but with a low degree of certainty due to high risk of bias
                      TEACH, 2020
                       
                      NCT04369742
                      RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
                      67/61 inconclusive
                      • inconclusive 80 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
                      • inconclusive 16 % increase in adverse events (PE) with a moderate degree of certainty due to some concern in risk of bias
                      Arshad (HCQ), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                      1202/409 suggested
                      • suggested 66 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                      Belgian Collaborative Group on COVID-19, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                      4542/3533 suggested
                      • suggested 32 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
                      Chen, 2020 OBSchloroquinecontrolCOVID 19 hospitalizedcritical
                      163/121 inconclusive
                        Chen, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                        163/121 safety concern
                        • statistically significant 51 % decrease in clinical improvement,clinical improvement (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                        Geleris, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                        811/565 inconclusive
                          Huang, 2020 OBSchloroquinecontrolCOVID 19 hospitalizedcritical
                          197/176 suggested
                          • suggested 5.1-fold increase in PCR-negative conversion (14-day) but with a very low degree of certainty due to critical risk of bias
                          Magagnoli (HC), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                          97/158 safety concern
                          • safety concern with statistically significant 1.6-fold increase in deaths,deaths (time to event analysis only)
                          Novales, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                          123/43 suggested
                          • suggested 93 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
                          Paccoud, 2020 OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
                          38/46 inconclusive
                            Rosenberg, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
                            -/- safety concern
                            • safety concern with 91 % increase in cardiac arrest (not statistically significant)
                            Sbidian (HCQ alone), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                            623/3792 safety concern
                            • statistically significant 25 % increase in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                            Singh, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
                            -/- inconclusive

                              COVID 19 all comers meta-analysis

                              ChiCTR2000030054-HCQ (Chen), 2020
                               
                              ChiCTR2000030054
                              RCThydroxychloroquinestandard of careCOVID 19 all comershigh
                              18/12 inconclusive
                                Gautret et al., 2020 NRahydroxychloroquinecontrolCOVID 19 all comersserious
                                20/16 suggested
                                • suggested 15.3-fold increase in PCR-negative conversion (PE) but with a low degree of certainty due to high risk of bias
                                a viral load reduction/disappearance is claimed but the numerous methological limits preclude any strong conclusion

                                COVID-19 mild to moderate meta-analysis

                                Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
                                 
                                NCT04322123
                                RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                                221/227 safety concern
                                • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                                HC-nCoV (Shanghai), 2020
                                 
                                NCT04261517
                                RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                                15/15 inconclusive
                                  NCT04333654, 2020
                                   
                                  NCT04333654
                                  RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
                                  -/- inconclusive
                                    NCT04342650, 2020
                                     
                                    NCT04342650
                                    RCTchloroquineplaceboCOVID-19 mild to moderateNA
                                    -/- inconclusive
                                      Zhaowei Chen, 2020
                                       
                                      ChiCTR2000029559
                                      RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
                                      31/31 inconclusive
                                        Zhaowei Chen, 2020
                                         
                                        ChiCTR2000029559
                                        RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
                                        31/31 suggested
                                        • suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
                                        • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias
                                        Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
                                        20/20 inconclusive

                                          COVID-19 severe or critically meta-analysis

                                          HYDRA, 2020
                                           
                                          NCT04315896
                                          RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
                                          75/77 inconclusive
                                          • inconclusive 1 % decrease in deaths (PE)
                                          REMAP-CAP-HCQ, 2020
                                           
                                          NCT02735707
                                          RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
                                          61/81 inconclusive
                                          • inconclusive 4 % increase in deaths (PE)
                                          REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
                                          Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
                                          84/97 inconclusive
                                            Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
                                            48/520 suggested
                                            • suggested 68 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

                                            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                                            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).